A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III/IV melanoma patients who are disease-free following the resection of macrometastases.
Yanina Jeanne Leona JansenVibeke KruseJurgen CorthalsKelly SchatsPieter-Jan van DamTeofila SeremetCarlo HeirmanLieve BrochezMark KockxKris ThielemansBart NeynsPublished in: Cancer immunology, immunotherapy : CII (2020)
TriMixDC-MEL id/iv as adjuvant therapy is tolerable and may improve the 1-year disease-free survival rate. Combination of optimized autologous monocyte-derived DC-formulations warrants further investigation in combination with currently approved adjuvant therapy options.
Keyphrases
- dendritic cells
- phase ii
- clinical trial
- free survival
- end stage renal disease
- open label
- immune response
- regulatory t cells
- ejection fraction
- bone marrow
- chronic kidney disease
- newly diagnosed
- endothelial cells
- cell therapy
- phase iii
- early stage
- randomized controlled trial
- peritoneal dialysis
- platelet rich plasma
- peripheral blood